Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient

• Status: Recruiting
• Trial end date: 2021-08-30
• Target enrollment: 0
• Participant gender: All

Summary

Determine the efficacy and safety of COVID19-0001-USR in the treatment of SARS-COV-2 infection in mild to moderate manifestations administered via nebulization/inhalation.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: United Medical Specialties

Criteria

Inclusion Criteria:

• Provide written consent before being included in the essay.

• Positive cases of COVID-19 (based on polymerase chain reaction or positive antigen test for SARS-CoV-2),

• Being diagnosed with mild to moderate SARS-COV-2 disease (COVID19)

• Symptomatic or asymptomatic patient, with good clinical appearance, Sat O2 at rest > 94% with room air, and without desaturation with ambulation, and without tachypnea,

• Respiratory rate < 20.

• Suspected cases of COVID-19, based on 3 criteria:

• Fever > 38 Degrees Celsius

• O2 saturation ≤94

• Abnormal laboratory indicators, any of them:

• Lymphopenia <1500 cells/m3

• C reactive protein >2 mg/L

• Ferritin >300g/L

Exclusion Criteria:

• Existing decompensated conditions such as Diabetes Mellitus, Hypertension, Coronary Insufficiency, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease (or any chronic or severe lung disease), Chronic Kidney Disease, Cancer, Immunosuppression, Mood Change

• Respiratory Frequency > 20 / min, Pulse > 120 bpm, systolic < 90 mmHg, diastolic < 60 mmHg

• The patient seems toxic and distressed, or, O2 at rest <93% in ambient air, or desaturation when ambulating

• Being diagnosed with severe SARS-COV-2 disease (COVID19)

• Patients with low oxygen saturation levels, need for ICU entry, need or likelihood of invasive mechanical ventilation

• Patients requiring bronchodilator treatment

• Patients with a known history of asthma and/or lung disease

• Patients with severe decompensated Chronic Obstructive Pulmonary Disease

• Patients who are unable to give consent or who are unable to follow up on the test group will be excluded